Ipca Laboratories Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/85ioyfmmh044wjh3iba9i0ht.pdf

Key Takeaways


Domestic Formulation: The Standout Performer


Margin Walk & Profitability

Harish Kamath: "Consolidated is more important than stand-alone. So as far as generic business is concerned, better let us go by consolidated guidelines."

Unichem Integration: Early Progress, Long Road

A.K. Jain: "So in current year, practically nothing of that nature will happen."

U.S. Re-entry: Building from Zero

Harish Kamath: "In these products, we were having a very big market share. The moment we went out, the prices increased. They have moderated, of course, subsequently. But still it is now better than what it was 10 years back."

Export Headwinds & Segment Weakness

Harish Kamath: "There are challenges... Considering all that, we are giving a muted guidance. If the situation improves, we may do better than what we are committing."

Subsidiaries & Other Businesses


R&D and Pipeline Investment

A.K. Jain: "But our initial calculations, where we were talking that on second year onwards, we should be able to get around INR200 crores kind of EBITDA margin."

Guidance & Commitments

CommitmentSpecificsTimeline
Standalone EBITDA marginAround 22% (raised from 21%)FY25 full year
Consolidated revenue growth~9% (cut from 10-11%)FY25 full year
India formulation growth11-12%FY25 full year
Unichem revenueINR 1,850-1,900 croresFY25 full year
Unichem EBITDA margin14-15%Remaining FY25 quarters
Unichem product launches4-5 formulation products per yearOngoing annual cadence
U.S. product launches (IPCA)~6 productsFY25 (3 shipped, 3 in pipeline)
U.S. product launches (Unichem own)5-6 new moleculesFY25
U.S. sales recognition startFrom Q3 onwardsFY25
R&D spend step-upTo ~4.25-4.5% of revenueFY26 (post biotech plant commissioning)
Unichem API sourcing from IPCATo begin~5-6 months from now
Unichem market extensionsLarger product range to other markets~1 year (regulatory process)
Unichem second-year EBITDAAround INR 200 croresFrom second year onwards

Key Metrics

MetricQ2 FY25
Consolidated revenue growth guidance (FY25)~9%, revised from earlier 10%–11%
Standalone EBITDA margin22.89%, vs 20.86% in Q2 FY24, improvement of ~2.03 ppt
Consolidated EBITDA margin19.10%, vs 17.64% in Q2 FY24, improvement of ~1.46 ppt
Standalone EBITDA margin guidance (FY25)~22%, revised from earlier ~21%
Domestic formulation growth11% for the quarter
IPM growth (IQVIA)~8%; IPCA delivered ~14% growth
Acute segment growth~12% for IPCA, vs market growth of ~7%
Chronic segment growth~17% for IPCA, vs market growth of ~10%
Market share2.14% in Q2 FY25, vs 2.04% in Q2 FY24, improvement of ~10 bps
Brands in top 300 IPM brands6 brands; CTD-T entered at rank 193
Generic business growth~15% overall for the quarter
Institutional business growth~85% for the quarter
Overall API business revenue₹319 cr, vs ₹335 cr in Q2 FY24, decline of ~5%
Domestic API growth~14% for the quarter
Unichem revenue guidance (FY25)₹1,850–₹1,900 cr, revised from earlier ~₹2,000 cr
Unichem Q2 EBITDA margin14.35%, improved from 12.52% in Q1 FY25; expected 14%–15% for remaining period
Unichem Q2 revenue growth~11%; consolidated sales improvement ~9.4%
Unichem U.S. business growth~12%–12.5%
Unichem pricing decline~1%–1.5%
Unichem Unit 1 Goa and Ghaziabad capacity utilization~70%–80%
Unichem Unit 2 Goa capacity utilization~20%
Unichem Bambi plant capacity utilization~30%–35%
IPCA goods shipped to U.S. (up to September)~₹30 cr worth; ~₹1–₹1.5 cr sales recorded, rest in stock
Branded formulation growth (H1 FY25)-2%
R&D spend (consolidated)~3% of turnover; may rise to ~4.25%–4.5% next FY after biotech plant commissioning
U.S. product launches planned (FY25)~6 products; 3 already shipped, 3 in pipeline
Unichem U.S. product launches planned (FY25)5–6 new molecules
Generic business growth guidance (FY25, consolidated)10%–12%; H1 growth was 2%
Generic business growth guidance (FY25, standalone IPCA)~8%
India business growth guidance (FY25)11%–12%
Institutional business annual revenue range₹300–₹400 cr going forward
Sales force~7,000 medical reps
Productivity per rep (H1 FY25)~₹4.62 lakh, vs ₹4.36 lakh in H1 FY24
Historical U.S. total business (2013–2015)~₹400 cr, including ~₹150–₹160 cr API business
Subsidiaries revenue (excluding Unichem)~₹80 cr
Trophic Wellness top line growth~10%–12%; bottom line growth ~15%–20%